Results 11 to 20 of about 1,533 (110)

Role of therapeutic drug monitoring in pulmonary infections : use and potential for expanded use of dried blood spot samples [PDF]

, 2015
Respiratory tract infections are among the most common infections in men. We reviewed literature to document their pharmacological treatments, and the extent to which therapeutic drug monitoring (TDM) is needed during treatment.
Akkerman, Onno W, Alffenaar, Jan-Willem C, Bolhuis, Mathieu S, Hofman, Susan, Koster, Remco A, Stove, Christophe, van Assen, Sander   +6 more
core   +2 more sources

A Newfangled Synthesis of Integrase Inhibitor Drug Substance Raltegravir Potassium

Asian Journal of Chemistry, 2019
Raltegravir sodium synthesis was achieved from its one of the key starting materials with retro synthetic approach, in which without using its critical starting material chemically known as 5-methyl-1,3,4-oxadiazole-2-carbonyl chloride and which is more unstable during the synthesis of raltegravir potassium.
S. Venkat Rao, Vamsi Krishna Potluri, Ramesh Babu Potluri   +2 more
openaire   +2 more sources

Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities [PDF]

, 2016
Renal toxicity in a 73 year old man using tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) is described. Reduced renal reserve, a higher exposure to co-medications and co-morbidities can present a challenge when assessing the risks ...
Barber, TJ, Girometti, N, Jones, R, Levy, J, McCormack, S, Sullivan, A   +5 more
core   +1 more source

Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study [PDF]

, 2016
For second-line antiretroviral therapy, WHO recommends a boosted protease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs).
Collier, Ann C, Harrison, Linda J, Hosseinipour, Mina C, Jarocki, Bernadette, Kim, Peter, Kumarasamy, Nagalingeswaran, La Rosa, Alberto M, Mellors, John W, Taiwo, Babafemi, Wallis, Carole L, Zheng, Lu   +10 more
core   +2 more sources

Crystal structure of 2-= (4-fluorobenzyl)sulfanyl-4-(2-methylpropyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile, C16H16FN3OS [PDF]

, 2016
C16H16FN3OS, triclinic, P1̅ (no. 2), a = 5.6885(3) Å, b = 9.4378(4) Å, c = 15.0736(7) Å, α = 84.037(4)°, β = 81.442(4)°, γ = 74.271(4)°, V = 768.56(7) Å3, Z = 2, R gt (F) = 0.0518, wR ref
Al-Deeb, O. A., El-Emam, A. Ali, García-Granda, Santiago, Ghabbour, H. A., Said Mohammed Abdelbaky, Mohammed   +4 more
core   +1 more source

Quantitative Reverse-phase High-performance Liquid Chromatographic Method for the Quantification of Raltegravir Potassium in Bulk and Dosage Forms

Journal of Young Pharmacists, 2019
Objectives: The aim of this present study is to develop an accurate, precise and linear Reverse-phase High-performance Liquid Chromatographic (RPHPLC) method for the estimation of raltegravir potassium in the bulk and pharmaceutical dosage form. Methods: The chromatographic system employs a reverse phase shim-pack C18 column, (150 x 4.6 mm; 5 μ) using ...
Krishna Veni Nagappan, Sonam Patel, Gullapalli Kowmudi, Gouru Santhosh Reddy   +3 more
openaire   +2 more sources

Etravirine pharmacokinetics in HIV-infected pregnant women [PDF]

, 2016
__Background__ The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women. __Methods__ IMPAACT P1026s and PANNA are on-going, non-randomized, open-label, parallel-group, multi-center phase-IV ...
Antinori, A. (Andrea), Best, B.M. (Brookie M.), Burger, D.M. (David), Capparelli, E.V. (Edmund V.), Chakhtoura, N. (Nahida), Colbers, A. (Angela), Ende, I.E. (Ineke) van der, Faetkenheuer, G. (Gerd), Fletcher, C.V. (Courtney V.), Giaquinto, C. (Carlo), Gilleece, Y. (Yvonne), Gingelmaier, A. (Andrea), Haberl, A. (Annette), Hawkins, D. (David), Ivanovic, J. (Jelena), Kabeya, K. (Kabamba), Kasteren, M.E.E. (Marjo) van, Lambert, J. (Julien), Lyons, F. (Fyona), Mirochnick, M. (Mark), Moltó, J. (José), Mulligan, N. (Nikki), Nellen, J.F.J.B. (Jeannine), Nicastri, E. (Emanuelle), Rockstroh, J. (Jürgen), Ruiter, A. (Annemiek de), Sadiq, T. (Tariq), Schalkwijk, S. (Stein), Schwarze-zander, C., Smith, E. (Elizabeth), Stek, A.M. (Alice M.), Taylor, G. (Graham), Tenorio, C.H. (Carmen Hidalgo), Ven, A. (André van der), Wang, J. (Jiajia), Weizsäcker, K. (Katharina), Wood, C. (Chris), Wyen, C. (Christoph)   +37 more
core   +1 more source

Cellular immune response induced by dna immunization of mice with drug resistant integrases of hiv-1 clade a offers partial protection against growth and metastatic activity of integrase-expressing adenocarcinoma cells [PDF]

, 2021
Funding Information: Funding: Experiments were supported by the grants of the Russian Science Fund 15-15-30039, Russian Fund for Basic Research 20-04-01034, Latvian Science Fund LZP 2018-2-03-08, and EU-ROPARTNER project “Strengthening and spreading ...
Agapkina, Yulia, Bayurova, Ekaterina, Eliseeva, Olesja, Fridrihsone, Ilze, Gordeychuk, Ilya, Gorodnicheva, Tatiana, Isaguliants, Maria, Jansons, Juris, Kilpelainen, Athina, Kostic, Linda, Krotova, Olga, Latanova, Anastasia, Latyshev, Oleg, Malkova, Anastasia, Mezale, Dzeina, Petkov, Stefan, Podschwadt, Philip, Saleem, Mina, Smirnova, Olga, Starodubova, Elizaveta, Wahren, Britta   +20 more
core   +1 more source

Cellular Active N-Hydroxyurea FEN1 Inhibitors Block Substrate Entry to the Active Site [PDF]

, 2016
The structure-specific nuclease human flap endonuclease-1 (hFEN1) plays a key role in DNA replication and repair and may be of interest as an oncology target. We present the first crystal structure of inhibitor-bound hFEN1 and show a cyclic N-hydroxyurea
A Desai, C McWhirter, Catrine L B Siöberg, CG Tomlinson, Claire McWhirter, Clifford D Jones, CY Kim, D Dorjsuren, D Martinez Molina, Daniel Martinez Molina, DM van Pel, E Bolderson, FH Niesen, FW Studier, G Dahl, GL Moldovan, H Panda, J Orans, J Willem M Nissink, J-C Hwang, JA Grasby, Jack C Exell, Jane A Grasby, JCD Houtman, JE Yeo, JH Chang, JL Illuzzi, JS Lam, Judit Debreczeni, K Fien, K Kim, K Schlacher, K Syson, K Yoshimoto, KJ McManus, L David Finger, L Zheng, LD Finger, LD Finger, LD Finger, LN Tumey, Mark J Thompson, N Patel, N Patel, N Tomimatsu, N Tomimatsu, P Emsley, P Singh, R Di Santo, RA Bambara, RM Clegg, RSN Fehrmann, S Keller, S Sakurai, S Waga, SE Tsutakawa, SS Parikh, ST Durant, Stephen T Durant, Steven J Shaw, T Izumi, T Nikolova, TD Craggs, Thomas A Ward, W Mark Abbott, WA Beard, WH Eschenfeldt, Y Shibata, Z Guo   +68 more
core   +2 more sources

Divalent metals and pH alter raltegravir disposition in vitro [PDF]

, 2012
Raltegravir shows marked pharmacokinetic variability in patients, with gastrointestinal pH and divalent-metal binding being potential factors. We investigated raltegravir solubility, lipophilicity, pKa, and permeativity in vitro to elucidate known ...

core   +1 more source